Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. - sprookjes - yvandenbroek - TriplyDB

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

http://www.wikidata.org/entity/Q34551403

about

Mutational profiling of kinases in glioblastoma.Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Combined surgical and molecular therapy: the gastrointestinal stromal tumor model Structural reengineering of imatinib to decrease cardiac risk in cancer therapy Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors Targeted therapy of gastrointestinal stromal tumours Somatic DNA mutation analysis in targeted therapy of solid tumours More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions The GIST of targeted therapy for malignant melanoma Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Unveiling changes in the landscape of patient populations in cancer early drug development Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations Pazopanib, a new therapy for metastatic soft tissue sarcoma Current management and prognostic features for gastrointestinal stromal tumor (GIST)Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles Key messages from the BFR14 trial of the French Sarcoma Group.Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.Strategies for modern biomarker and drug development in oncology.Discovering Outliers of Potential Drug Toxicities Using a Large-scale Data-driven Approach Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.[Hemato-oncological diseases].Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors Gastrointestinal stromal tumor.Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data.

P2860

Q21261249-28A6BF73-1217-41B4-8147-5AF8A24CD252 Q24200254-75F04EEC-2E4C-4492-A71A-73D4E6DD150F Q24234239-715C0E9B-9504-480D-9448-43290D96AC3A Q24234579-701820D1-893F-4030-81F4-A1A18E0F32B4 Q24235034-C79E1174-0467-4C4C-91D3-BEDD51759FA3 Q24240660-197A3F0C-FA19-4936-8AD8-995F5FF347DC Q24675987-FD02F2F3-305D-4A1E-80E8-1B8B39BC9E32 Q24685557-D906C140-AA5B-4D0A-B9A8-FB810DC4CF79 Q24685605-A78334E8-AF97-4180-8909-57ABB594E8C6 Q26738567-C0E00CBF-C894-4EAB-86A1-2298EF5BBE4B Q26745633-74B1C70B-68E8-42D6-8B58-F9E368DA504B Q26770324-EA794B74-D52A-41A5-8B1B-A60F5D988D20 Q26781662-A36C53C6-EEFE-4EC3-B02C-F1F83E3AE8BF Q26799387-1F8CA7CC-04DD-4835-9183-C18EE4317CAA Q26827092-4E7F4C3C-CF4F-46F6-84BA-8D0FB5E42A46 Q26830525-D0888BE0-8B02-4A23-BE96-C4F1985622FD Q26866517-65621051-3724-4AC8-91B7-249EDB19A388 Q27027632-FF3FC573-9BAE-4B24-B27E-457AC41BD27C Q27653496-F4A40BE5-0ABC-4A28-8771-F5FDE7677006 Q27851455-5FCB5FEE-1FEE-42FE-BA2D-7294472D03F1 Q27851744-AA182504-C341-46FA-AFF1-EE0E28046053 Q27853181-9439F207-1101-47AB-B648-C7A724A121CB Q28073826-472DD938-1850-41E0-858F-C110013044ED Q28247449-7B1ECC1B-CBCE-4591-8E79-E040BE2313EB Q28287163-DE347215-90BF-44F0-9C04-58F1C1F768FA Q28391684-EF329054-2EDE-4331-A75B-F6CBAA6A3444 Q28484970-89FF8918-F928-4B07-B158-78955A5AB2F4 Q28765146-454A5C8D-FF6C-4898-8392-5CBD224C3CD0 Q29617464-6859142E-4080-420F-B694-806F69B550B3 Q30245384-817B2CD7-55FC-464F-8ADF-53C9128E790B Q30245586-08151F5D-9922-4940-864D-76E33F5C87DE Q30485073-DE7CB219-1965-4612-A00C-81F8E868D531 Q30590270-659AF620-63F4-4346-B578-C385DB6CAFAA Q31140868-32623B2F-D08E-4C3F-A569-9DF84AA1E400 Q33390293-2FD40806-2A4C-46D2-BEA7-8880BA98F7FE Q33392955-29E46072-533A-4FE1-9E71-722E59710945 Q33410075-65AB549F-55E0-4620-9FE5-8FB8DE448047 Q33412724-C2E77188-2A23-4FA1-82E7-C6A5FBB94887 Q33489084-2248D1DB-4F0A-4675-9053-9252FB769910 Q33515723-9B0D628C-A328-4F74-8494-1CB21E03A257

P2860

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

http://www.wikidata.org/entity/Q34551403

description

2004 nî lūn-bûn

@nan

2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Progression-free survival in g ...... se imatinib: randomised trial.

@ast

Progression-free survival in g ...... se imatinib: randomised trial.

@en

Progression-free survival in g ...... se imatinib: randomised trial.

@nl

type

label

Progression-free survival in g ...... se imatinib: randomised trial.

@ast

Progression-free survival in g ...... se imatinib: randomised trial.

@en

Progression-free survival in g ...... se imatinib: randomised trial.

@nl

prefLabel

Progression-free survival in g ...... se imatinib: randomised trial.

@ast

Progression-free survival in g ...... se imatinib: randomised trial.

@en

Progression-free survival in g ...... se imatinib: randomised trial.

@nl

P1433

Q34551403-EA0D99B8-E173-4277-B2B6-8A2EAF95500C

P1476

Q34551403-2CBDF2BE-DF8B-4CAE-8EBD-15E2C416C223

P2093

Q34551403-15ABB7DF-2DEE-4555-AA4C-0F44B2E972F7

Q34551403-523D3E14-81F4-4063-97F8-CB317BF34A3A

Q34551403-6650D9EA-A3E3-4AD6-8DF3-1C50E3D79BBA

Q34551403-6F7636E9-5413-4F17-B915-65E52B703B10

Q34551403-7710A76C-6D3B-4079-83A5-D15B4EDDF4E4

Q34551403-CCF7CDC9-806A-4A7F-A61C-9F5A2D1C3144

Q34551403-D47323AF-2A36-4853-AFB9-90855068E67B

Q34551403-E0F19F6D-523E-4CD8-969E-B85DABBE0CC7

Q34551403-EE785FD8-AB00-496B-9101-675FF4941491

P304

Q34551403-EDB49C92-E3A2-4CB7-BF0B-FCCF84764AD3

P31

Q34551403-07661879-9cbc-4e3c-aa45-db3f22a61b36

Q34551403-5EDBE1C9-BCDB-4BDF-8B33-374EF232BCB0

P356

Q34551403-DA3E625D-56C9-40EB-810D-40F3497D15B8

P407

Q34551403-AC3A11DC-2216-478E-A278-F221DDCBFAC8

P433

Q34551403-C97B092C-96E8-4587-A72B-0DB81628C563

P478

Q34551403-33741580-72AA-4B82-8B65-4C6AE8918F39

P50

Q34551403-72A4CD7A-7423-4C4E-BE29-E2AC622610F5

Q34551403-810AF7DD-AFA2-43E4-8E01-5721C2D051C9

Q34551403-E9B273DE-67E3-4E36-AEEA-382469C9637A

P577

Q34551403-4E7742CB-4B8D-401E-8092-F844CC939F94

P698

Q34551403-CBD28534-83DB-4346-B82A-D065F399AED8

P356

S0140-6736(04)17098-0

P1433

P1476

Progression-free survival in g ...... se imatinib: randomised trial.

@en

P2093

Allan van Oosterom

http://www.w3.org/2001/XMLSchema#string

Axel LeCesne

http://www.w3.org/2001/XMLSchema#string

Ian Judson

http://www.w3.org/2001/XMLSchema#string

Jaap Verweij

http://www.w3.org/2001/XMLSchema#string

John Zalcberg

http://www.w3.org/2001/XMLSchema#string

Martine Van Glabbeke

http://www.w3.org/2001/XMLSchema#string

Pancras C W Hogendoorn

http://www.w3.org/2001/XMLSchema#string

Peter Reichardt

http://www.w3.org/2001/XMLSchema#string

Rolf Issels

http://www.w3.org/2001/XMLSchema#string

P304

1127-1134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(04)17098-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

9440

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Giovanni Casali

Rossella Bertulli

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15451219

http://www.w3.org/2001/XMLSchema#string